Erythrocyte membrane encapsulated gambogic acid nanoparticles as a therapeutic for hepatocellular carcinoma

Gambogic acid (GA) is a potential clinical anticancer drug that can exert antitumor effects via various molecular mechanisms. Notwithstanding, GA's low water solubility, poor stability, short half-life, and unavoidable toxic side effects have significantly hampered its clinical application. Erythrocyte membrane-coated nanoparticles (RBCM-NPs) improve drug's physicochemical properties, biocompatibility, and pharmacokinetic behaviors, allowing for long-term drug circulation and passive targeting. In this study, a novel biomimetic drug delivery system (DDS) against hepatocellular carcinoma was prepared by covering RBCM on GPP-NPs (GA-loaded mPEG-PLA NPs) to develop the [email protected] In comparison to RBCM-free nanoparticles and free GA, [email protected] improved the drug's water solubility, stability, safety, and anti-tumor activity in vivo. We expect that this bionic nanoparticle composite can expand the clinical applicability of GA and provide a feasible solution for the research and development of GA's nano-formulation.